Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judit Pallos

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Molecular and Cellular Neurosciences|July 8, 2008
CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 miceBarbara L Apostol, Danielle A Simmons, Chiara Zuccato, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 6, 2003
A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in DrosophilaBarbara L Apostol, Alexsey Kazantsev, Simona Raffioni, et al.
Science (New York, N.Y.)|April 6, 2004
SUMO modification of Huntingtin and Huntington's disease pathologyJoan S Steffan, Namita Agrawal, Judit Pallos, et al.
Neurobiology of Disease|May 17, 2012
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's diseaseHaiqun Jia, Judit Pallos, Vincent Jacques, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2010
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesisRuth Luthi-Carter, David M Taylor, Judit Pallos, et al.
Cell Reports|July 23, 2013
SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulationJacqueline Gire O'Rourke, Jaclyn R Gareau, Joseph Ochaba, et al.
Cell Chemical Biology|July 19, 2016
SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease ModelsLuisa Quinti, Malcolm Casale, Sébastien Moniot, et al.
EMBO Molecular Medicine|July 29, 2010
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington diseaseStephen J McConoughey, Manuela Basso, Zoya V Niatsetskaya, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Molecular and Cellular Neurosciences|July 8, 2008
CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 miceBarbara L Apostol, Danielle A Simmons, Chiara Zuccato, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 6, 2003
A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in DrosophilaBarbara L Apostol, Alexsey Kazantsev, Simona Raffioni, et al.
Science (New York, N.Y.)|April 6, 2004
SUMO modification of Huntingtin and Huntington's disease pathologyJoan S Steffan, Namita Agrawal, Judit Pallos, et al.
Neurobiology of Disease|May 17, 2012
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's diseaseHaiqun Jia, Judit Pallos, Vincent Jacques, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2010
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesisRuth Luthi-Carter, David M Taylor, Judit Pallos, et al.
Cell Reports|July 23, 2013
SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulationJacqueline Gire O'Rourke, Jaclyn R Gareau, Joseph Ochaba, et al.
Cell Chemical Biology|July 19, 2016
SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease ModelsLuisa Quinti, Malcolm Casale, Sébastien Moniot, et al.
EMBO Molecular Medicine|July 29, 2010
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington diseaseStephen J McConoughey, Manuela Basso, Zoya V Niatsetskaya, et al.
Pageof 2